PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical…
ANN ARBOR, Mich., June 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a…